Show simple item record

dc.contributor.authorLucraft, H H
dc.contributor.authorPalmer, Michael K
dc.date.accessioned2011-05-31T12:08:54Z
dc.date.available2011-05-31T12:08:54Z
dc.date.issued1982-11
dc.identifier.citationRandomised clinical trial of levonantradol and chlorpromazine in the prevention of radiotherapy-induced vomiting. 1982, 33 (6):621-2 Clin Radiolen
dc.identifier.issn0009-9260
dc.identifier.pmid6754212
dc.identifier.doi10.1016/S0009-9260(82)80383-8
dc.identifier.urihttp://hdl.handle.net/10541/132389
dc.description.abstractLevonantradol is a cannabis derivative. Cannabinoid anti-emetics are being assessed in cancer chemotherapy but have been little used in radiotherapy to date. A pilot study and randomised trial compared the anti-emetic effect of a standard drug (Chlorpromazine 26 mg) with Levonantradol at two doses (0.5 and 0.75 mg) in patients receiving palliative single fraction radiotherapy to sites likely to cause nausea and vomiting. Most patients were out-patients. Both drugs were well tolerated. The frequency of vomiting was similar in all three groups in both the pilot study and randomised trial.
dc.language.isoenen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntiemetics
dc.subject.meshChlorpromazine
dc.subject.meshClinical Trials as Topic
dc.subject.meshHumans
dc.subject.meshMiddle Aged
dc.subject.meshPhenanthridines
dc.subject.meshPilot Projects
dc.subject.meshRadiation Injuries
dc.subject.meshRadiotherapy
dc.subject.meshRandom Allocation
dc.subject.meshVomiting
dc.titleRandomised clinical trial of levonantradol and chlorpromazine in the prevention of radiotherapy-induced vomiting.en
dc.typeArticleen
dc.contributor.departmentDepartment of Radiotherapy and Oncology, Christie Hospital and Holt Radium Institute, Manchester, U.K.en
dc.identifier.journalClinical Radiologyen
html.description.abstractLevonantradol is a cannabis derivative. Cannabinoid anti-emetics are being assessed in cancer chemotherapy but have been little used in radiotherapy to date. A pilot study and randomised trial compared the anti-emetic effect of a standard drug (Chlorpromazine 26 mg) with Levonantradol at two doses (0.5 and 0.75 mg) in patients receiving palliative single fraction radiotherapy to sites likely to cause nausea and vomiting. Most patients were out-patients. Both drugs were well tolerated. The frequency of vomiting was similar in all three groups in both the pilot study and randomised trial.


Files in this item

This item appears in the following Collection(s)

Show simple item record